//
Douglas L. Arnold
Ludwig Kappos
Patrick Vermersch
Ralf Gold
Amit Bar-Or
Gavin Giovannoni
Bruce A.C. Cree
Daniela Piani-Meier
Shannon Ritter
Goeril Karlsson
Frank Dahlke
Thomas Hach
Robert J. Fox
UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA
FHU Imminent, Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille, Lille, France
Department for Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany
Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland
Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland, OH, USA
NeuroRx Research, Montreal, QC, Canada, Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
Novartis AG, Basel, Switzerland
Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
United States
France
Canada
Germany
Switzerland
United Kingdom
Novartis AG
Central Nervous System (CNS)
Multiple Sclerosis
N/A
Siponimod
N/A
Randomized
Placebo Control
Open Label
III
N/A
N/A
Final